Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KARAN LAL

Allopathic & Osteopathic Physicians Dermatology Pediatric Dermatology

NPI
1679928832
CMS profile
7784041
Location
SCOTTSDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$237,600.62

406 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 5 of 9; records 201–250 of 406 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KARAN LAL

NPI 1679928832 · CMS profile ID 7784041

Allopathic & Osteopathic Physicians / Dermatology / Pediatric Dermatology

SCOTTSDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 9; records 201–250 of 406 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679928832?year=2024&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KARAN LAL, NPI 1679928832, CMS profile ID 7784041. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 9; records 201–250 of 406 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679928832?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). KARAN LAL, NPI 1679928832, CMS profile ID 7784041. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 9; records 201–250 of 406 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679928832?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
KARAN LAL, NPI 1679928832, CMS profile ID 7784041, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 9; records 201–250 of 406 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1679928832?year=2024&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

406 matching records · $237,600.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 406 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 406.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Incyte Corporation $105.2707/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141171429 CMS
Galderma Laboratories, L.P. $139.4907/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145311133 CMS
Galderma Laboratories, L.P. $35.3407/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145311135 CMS
Galderma Laboratories, L.P. $33.0607/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145311137 CMS
Galderma Laboratories, L.P. $91.2107/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145311139 CMS
Galderma Laboratories, L.P. $339.0107/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145311129 CMS
Galderma Laboratories, L.P. $251.9707/26/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145311131 CMS
ABBVIE INC. $132.7307/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104130746 CMS
ABBVIE INC. $465.6807/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104192910 CMS
PFIZER INC. $10.1607/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131780606 CMS
Galderma Laboratories, L.P. $56.7007/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145311127 CMS
Verrica Pharmaceuticals Inc. $47.8707/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118383100 CMS
E.R. Squibb & Sons, L.L.C. $19.3207/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101353748 CMS
Regeneron Healthcare Solutions, Inc. $31.4107/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114094987 CMS
Regeneron Healthcare Solutions, Inc. $4.5707/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114094989 CMS
Regeneron Healthcare Solutions, Inc. $50.1307/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114094991 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $5.9207/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152166810 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $3,249.0007/18/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152166824 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $120.8807/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152166828 CMS
ABBVIE INC. $21.2707/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104130742 CMS
ABBVIE INC. $31.1107/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104130744 CMS
Galderma Laboratories, L.P. $7.2107/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145311123 CMS
Galderma Laboratories, L.P. $6.1807/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145311125 CMS
Novartis Pharmaceuticals Corporation $23.2307/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087130124 CMS
Arcutis Biotherapeutics, Inc. $76.9707/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121056669 CMS
Galderma Laboratories, L.P. $3,300.0007/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145311121 CMS
Verrica Pharmaceuticals Inc. $36.2907/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118383098 CMS
Arcutis Biotherapeutics, Inc. $82.9607/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121056671 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $4,065.0007/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118108887 CMS
Dermavant Sciences, Inc. $2,400.0007/11/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127894667 CMS
Dermavant Sciences, Inc. $108.6207/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127894671 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $937.5007/08/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118108885 CMS
Dermavant Sciences, Inc. $6.1907/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127894660 CMS
Dermavant Sciences, Inc. $7.3407/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127894663 CMS
Paratek Pharmaceuticals, Inc. $16.8507/02/2024 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1113907245 CMS
ABBVIE INC. $14.0806/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104130740 CMS
Dermavant Sciences, Inc. $3.8706/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127894656 CMS
Galderma Laboratories, L.P. $123.8106/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145311119 CMS
Lilly USA, LLC $11.9206/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135118819 CMS
ABBVIE INC. $8.5606/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104130738 CMS
GENZYME CORPORATION $22.5606/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139672259 CMS
Galderma Laboratories, L.P. $3,850.0006/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145311111 CMS
Galderma Laboratories, L.P. $11.6106/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145311113 CMS
Galderma Laboratories, L.P. $5.9706/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145311115 CMS
Galderma Laboratories, L.P. $3,850.0006/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145311117 CMS
ABBVIE INC. $1,295.8306/14/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103159878 CMS
ABBVIE INC. $2,875.0006/14/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103159880 CMS
Galderma Laboratories, L.P. $6.8706/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145311109 CMS
Janssen Biotech, Inc. $18.1206/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078281857 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $72.8306/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118108883 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $21.90 1
PY2021 $486.62 19
PY2022 $25,839.29 124
PY2023 $123,800.23 240
PY2024 $237,600.62 406
PY2025 $256,238.03 471

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $118,489.12 172
PY2024 Principal investigator $295,151.11 188
PY2023 Principal investigator $68,980.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

172 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $510.90 12/24/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577295
Principal investigator 1 Incyte Corporation $92.00 12/10/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577259
Principal investigator 1 Incyte Corporation $234.00 12/10/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577265
Principal investigator 1 Incyte Corporation $506.00 12/10/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577271
Principal investigator 1 Incyte Corporation $130.00 12/10/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577283
Principal investigator 1 Incyte Corporation $4,000.00 12/05/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577240
Principal investigator 1 Incyte Corporation $4,000.00 12/05/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577245
Principal investigator 1 Incyte Corporation $16.18 12/01/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500252
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500255
Principal investigator 1 Incyte Corporation $49.77 12/01/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500261
Principal investigator 1 Incyte Corporation $45.80 12/01/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500265
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500267
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500270
Principal investigator 1 Incyte Corporation $981.10 11/24/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577205
Principal investigator 1 Incyte Corporation $1,614.00 11/24/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577229
Principal investigator 1 Incyte Corporation $1,614.00 11/24/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577235
Principal investigator 1 Incyte Corporation $389.00 11/24/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577289
Principal investigator 1 Incyte Corporation $65.00 11/07/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577211
Principal investigator 1 Incyte Corporation $112.00 11/07/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577216
Principal investigator 1 Incyte Corporation $117.00 11/07/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577223
Principal investigator 1 Incyte Corporation $253.00 11/07/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577251
Principal investigator 1 Incyte Corporation $46.00 11/07/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577277
Principal investigator 1 Incyte Corporation $63.00 09/17/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577101
Principal investigator 1 Incyte Corporation $130.00 09/15/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577046
Principal investigator 1 Incyte Corporation $92.00 09/15/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577109
Principal investigator 1 Incyte Corporation $234.00 09/15/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577115
Principal investigator 1 Incyte Corporation $506.00 09/15/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577121
Principal investigator 1 Incyte Corporation $4,000.00 09/12/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577126
Principal investigator 1 Incyte Corporation $350.00 09/12/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577151
Principal investigator 1 Incyte Corporation $750.00 08/20/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577057
Principal investigator 1 Incyte Corporation $4,000.00 08/20/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577062
Principal investigator 1 Incyte Corporation $500.00 08/20/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577066
Principal investigator 1 Incyte Corporation $6,000.00 08/20/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577072
Principal investigator 1 Incyte Corporation $4,000.00 08/18/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577051
Principal investigator 1 Incyte Corporation $63.00 08/18/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577191
Principal investigator 1 Incyte Corporation $4,000.00 08/18/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577198
Principal investigator 1 Incyte Corporation $1,750.00 08/13/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240577133
Principal investigator 1 Incyte Corporation $2,110.50 08/01/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577097
Principal investigator 1 Incyte Corporation $4,000.00 07/11/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577155
Principal investigator 1 Incyte Corporation $350.00 07/11/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577161
Principal investigator 1 Incyte Corporation $63.00 07/11/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577171
Principal investigator 1 Incyte Corporation $339.70 07/09/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577079
Principal investigator 1 Incyte Corporation $4,000.00 07/09/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577086
Principal investigator 1 Incyte Corporation $126.00 07/09/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577090
Principal investigator 1 Incyte Corporation $1,603.00 07/09/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577185
Principal investigator 1 Incyte Corporation $63.00 07/02/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577138
Principal investigator 1 Incyte Corporation $539.00 07/02/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577146
Principal investigator 1 Incyte Corporation $4,000.00 07/02/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577165
Principal investigator 1 Incyte Corporation $75.00 07/02/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577179
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500223
Principal investigator 1 Incyte Corporation $4.86 07/01/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500227
Principal investigator 1 Incyte Corporation $49.36 07/01/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500232
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500235
Principal investigator 1 Incyte Corporation $0.62 07/01/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500240
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500244
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500248
Principal investigator 1 Incyte Corporation $750.00 05/27/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240576959
Principal investigator 1 Avita Medical Americas, LLC $1,175.00 05/16/2025 Non-covered Recipient Entity
Physicians Research Group II, LLC
CTP010 Additional Vitiligo Study No dispute reported 06/30/2026 1171903465
Principal investigator 1 Incyte Corporation $4,000.00 05/16/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240576989
Principal investigator 1 Incyte Corporation $120.00 05/16/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577035
Principal investigator 1 Incyte Corporation $126.00 05/16/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577040
Principal investigator 1 Incyte Corporation $8.45 05/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500201
Principal investigator 1 Incyte Corporation $12.15 05/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500206
Principal investigator 1 Incyte Corporation $1,950.20 05/02/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577023
Principal investigator 1 Incyte Corporation $1,603.00 05/02/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577027
Principal investigator 1 Incyte Corporation $350.00 04/23/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240576971
Principal investigator 1 Incyte Corporation $1,282.40 04/09/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577001
Principal investigator 1 Incyte Corporation $1,603.00 04/09/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577006
Principal investigator 1 Incyte Corporation $350.00 04/04/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240576965
Principal investigator 1 Incyte Corporation $350.00 04/04/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240576977
Principal investigator 1 Incyte Corporation $4,000.00 04/04/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240576983
Principal investigator 1 Incyte Corporation $63.00 04/04/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240576995
Principal investigator 1 Incyte Corporation $250.00 04/04/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577014
Principal investigator 1 Incyte Corporation $32.36 04/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500209
Principal investigator 1 Incyte Corporation $32.28 04/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500215
Principal investigator 1 Incyte Corporation $68.70 04/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500219
Principal investigator 1 Incyte Corporation $2,110.50 03/12/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240576920
Principal investigator 1 Incyte Corporation $1,500.00 03/04/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240577301
Principal investigator 1 Incyte Corporation $8,000.00 03/04/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240577308
Principal investigator 1 Incyte Corporation $14.58 03/03/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500099
Principal investigator 1 Incyte Corporation $148.08 03/03/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500103
Principal investigator 1 Incyte Corporation $1.86 03/03/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500109
Principal investigator 1 Incyte Corporation $49.32 03/03/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500121
Principal investigator 1 Incyte Corporation $49.32 03/03/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500125
Principal investigator 1 Incyte Corporation $49.32 03/03/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500129
Principal investigator 1 Incyte Corporation $49.32 03/03/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500134
Principal investigator 1 Incyte Corporation $4,000.00 02/24/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240576946
Principal investigator 1 Incyte Corporation $1,603.00 02/10/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240576880
Principal investigator 1 Incyte Corporation $1,603.00 02/10/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240576885
Principal investigator 1 Incyte Corporation $1,141.90 02/10/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240576942
Principal investigator 1 Incyte Corporation $45.00 02/07/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240500494
Principal investigator 1 Incyte Corporation $944.00 02/07/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240576891
Principal investigator 1 Incyte Corporation $126.00 02/07/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240576898
Principal investigator 1 Incyte Corporation $500.00 02/07/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240576914
Principal investigator 1 Incyte Corporation $4,000.00 02/07/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240576936
Principal investigator 1 Incyte Corporation $114.50 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240499929
Principal investigator 1 Incyte Corporation $190.62 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240499944
Principal investigator 1 Incyte Corporation $9.45 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240499959
Principal investigator 1 Incyte Corporation $1.40 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240499963
Principal investigator 1 Incyte Corporation $9.72 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240499968
Principal investigator 1 Incyte Corporation $3.43 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240499971
Principal investigator 1 Incyte Corporation $3.43 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240499976
Principal investigator 1 Incyte Corporation $9.90 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240499980
Principal investigator 1 Incyte Corporation $9.90 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240499984
Principal investigator 1 Incyte Corporation $12.20 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240499988
Principal investigator 1 Incyte Corporation $27.75 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240499992
Principal investigator 1 Incyte Corporation $13.60 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240499995
Principal investigator 1 Incyte Corporation $103.25 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240499999
Principal investigator 1 Incyte Corporation $6.76 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500003
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500007
Principal investigator 1 Incyte Corporation $29.52 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500011
Principal investigator 1 Incyte Corporation $119.08 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500015
Principal investigator 1 Incyte Corporation $6.88 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500019
Principal investigator 1 Incyte Corporation $1.47 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500022
Principal investigator 1 Incyte Corporation $33.96 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500026
Principal investigator 1 Incyte Corporation $2.04 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500030
Principal investigator 1 Incyte Corporation $0.44 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500035
Principal investigator 1 Incyte Corporation $3.32 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500039
Principal investigator 1 Incyte Corporation $120.06 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500043
Principal investigator 1 Incyte Corporation $120.06 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500047
Principal investigator 1 Incyte Corporation $104.56 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500051
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500055
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500060
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500064
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500069
Principal investigator 1 Incyte Corporation $54.62 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500073
Principal investigator 1 Incyte Corporation $22.29 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500077
Principal investigator 1 Incyte Corporation $22.29 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500081
Principal investigator 1 Incyte Corporation $76.92 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500084
Principal investigator 1 Incyte Corporation $24.36 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500090
Principal investigator 1 Incyte Corporation $43.32 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500094
Principal investigator 1 Incyte Corporation $6.25 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500138
Principal investigator 1 Incyte Corporation $1.02 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500148
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500152
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500155
Principal investigator 1 Incyte Corporation $2.94 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500159
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500163
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500167
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500170
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500174
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500195
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240500197
Principal investigator 1 Avita Medical Americas, LLC $7,950.00 01/23/2025 Non-covered Recipient Entity
Physicians Research Group II, LLC
CTP010 Additional Vitiligo Study No dispute reported 06/30/2026 1171903463
Principal investigator 1 Incyte Corporation $10.00 01/21/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240577313
Principal investigator 1 Incyte Corporation $1,759.00 01/15/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240576868
Principal investigator 1 Incyte Corporation $1,266.80 01/15/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240576903
Principal investigator 1 Incyte Corporation $189.00 01/08/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240576874
Principal investigator 1 Incyte Corporation $350.00 01/08/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240576907
Principal investigator 1 Incyte Corporation $1,000.00 01/08/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240576927
Principal investigator 1 Incyte Corporation $259.70 01/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240499881
Principal investigator 1 Incyte Corporation $100.70 01/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240499886
Principal investigator 1 Incyte Corporation $196.10 01/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240499890
Principal investigator 1 Incyte Corporation $201.40 01/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240499894
Principal investigator 1 Incyte Corporation $68.90 01/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240499898
Principal investigator 1 Incyte Corporation $84.80 01/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240499902
Principal investigator 1 Incyte Corporation $37.66 01/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240499906
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240499911
Principal investigator 1 Incyte Corporation $53.00 01/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240499916
Principal investigator 1 Incyte Corporation $63.60 01/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240499919
Principal investigator 1 Incyte Corporation $21.20 01/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240499924
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240499933
Principal investigator 1 Incyte Corporation $5.38 01/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240499938
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240499948
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240499952
Principal investigator 1 Incyte Corporation $26.50 01/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240499955
Principal investigator 1 Incyte Corporation $31.80 01/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500113
Principal investigator 1 Incyte Corporation $31.80 01/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500117
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500142
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500178
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500182
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500186
Principal investigator 1 Incyte Corporation $53.00 01/02/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500190